Patients with locally advanced oral squamous cell carcinoma (OSCC) have poor outcomes with standard care. Neoadjuvant therapy is shown to be effective for these patients. In the randomized, two-arm, phase 2, non-comparative trial, we investigate the efficacy and safety of the neoadjuvant programmed cell death 1 (PD-1) inhibitor camrelizumab with or without docetaxel-cisplatin-5-fluorouracil (TPF) chemotherapy in patients with resectable locally advanced OSCC. Patients with stage III-IVA OSCC receive neoadjuvant therapy with three cycles of camrelizumab (arm Cam) with or without two cycles of TPF chemotherapy (arm Cam+TPF), followed by surgery and adjuvant therapy. Major pathological response (MPR) is achieved in both arm Cam (5/34, 14.7%) and arm Cam+TPF (26/34, 76.4%). With a median follow-up of 32 months, the 2-year event-free survival (EFS) rate of arm Cam and Cam+TPF is 52.9% and 91.2%, respectively. This work demonstrates feasibility and safety for immunochemotherapy in the neoadjuvant setting for OSCC. This study was registered at ClinicalTrials.gov (NCT04649476).
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11866509 | PMC |
| http://dx.doi.org/10.1016/j.xcrm.2025.101930 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[Merkel cell carcinoma: An update].
Bull Cancer
March 2025
Dermatologie, CHU de Tours, Tours, France; Réseau CARADERM, France.
Merkel cell carcinoma (MCC) is a rare skin cancer that mainly affects the elderly, and whose incidence is increasing. Although the exact origin of this cancer remains uncertain, research in recent years has revealed that MCC develops through two oncogenesis pathways: virally induced by the Merkel polyomavirus (80% of cases) and induced by mutations linked to ultraviolet rays (20% of cases). MCC is an aggressive cancer, with a high mortality rate and limited therapeutic options in advanced stage.
View Article and Find Full Text PDFOncology: Brain asymmetries in language-relevant brain tumors.
Handb Clin Neurol
March 2025
Donders Institute for Brain Cognition Behaviour, Radboud University, Nijmegen, The Netherlands; Brain Connectivity and Behaviour Laboratory, Sorbonne Universities, Paris, France; Centre for Neuroimaging Sciences, Department of Neuroimaging, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom.
Brain tumors are classified as rare diseases, with an annual occurrence of 300,000 cases and account for an annual loss of 241,000 lives, highlighting their devastating nature. Recent advancements in diagnosis and treatment have significantly improved the management and care of brain tumors. This chapter provides an overview of the common types of primary brain tumors affecting language functions-gliomas and meningiomas.
View Article and Find Full Text PDFDosimetry and Toxicity Comparison of Three-Dimensional Conformal Radiation Therapy and Intensity-Modulated Radiation Therapy in Locally Advanced Lung Cancer Across a Large Statewide Quality Collaborative.
Int J Radiat Oncol Biol Phys
March 2025
Department of Radiation Oncology, University of Michigan, Ann Arbor, MI. Electronic address:
Purpose/objective(s): Use of intensity-modulated radiation therapy (IMRT) versus three-dimensional conformal external beam radiation therapy (3D-CRT) for definitive chemoradiation therapy (CRT) in locally advanced non-small cell lung cancer (LA-NSCLC) has been associated with decreased late pneumonitis, decreased high dose to the heart (itself associated with improved overall survival), and improved patient quality of life. In a statewide radiation oncology quality consortium, we sought to evaluate the impact of IMRT versus 3D-CRT treatment technique on dosimetry and toxicity.
Materials/methods: From 2012 to 2022, 1746 LA-NSCLC patients meeting inclusion criteria underwent definitive RT (90% CRT) with either 3D-CRT (n=313) or IMRT (n=1433) and were enrolled in the [quality consortium] prospective, multicenter statewide initiative.
20-Week Toxicity Study of Rotigotine Behenate Extended-Release Microspheres for Intramuscular Injection in Sprague Dawley Rats.
Food Chem Toxicol
March 2025
School of Pharmacy, Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), Ministry of Education, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, Yantai University, Yantai, Shandong 264003, China. Electronic address:
Based on the concept of continuous dopaminergic stimulation (CDS), Rotigotine Behenate extended-release microspheres for injection (RBEM) are currently under development. To support human clinical trials of RBEM, a 20-week repeat-dose toxicity study was conducted. SD rats intramuscularly received RBEM (60, 180, and 540 mg/kg) once every 4 weeks for 5 repeated doses followed by a 12-week recovery period, no clear sex difference was noted in the plasma exposure of rotigotine in rats, and the exposure generally increased in a dose-proportional manner.
View Article and Find Full Text PDF[A Case of Robot-Assisted Total Pelvic Exenteration for Locally Advanced Rectal Cancer with Vaginal Invasion].
Gan To Kagaku Ryoho
February 2025
Dept. of Gastroenterological Surgery, Sakai City Medical Center.
A 66-year-old woman presented with discharge of necrotic tissue and bleeding from the vagina during uterine cancer screening. She was diagnosed with lower rectal cancer cT4b(vagina)N3M0, cStage Ⅲc. As the tumor protruded into the lumen from the posterior vaginal wall, preservation of the anterior vaginal wall was challenging.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!